<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43489">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02540174</url>
  </required_header>
  <id_info>
    <org_study_id>ALTAKRA-1405</org_study_id>
    <nct_id>NCT02540174</nct_id>
  </id_info>
  <brief_title>Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer : Interest of an Addiction Treatment</brief_title>
  <acronym>ALTAKRA-1405</acronym>
  <official_title>Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer : Interest of Integrating the Addiction Treatment to the Initial Cancer Treatment Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Régional de Référence en Cancérologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, interventional, randomized study among patients with a first lung or
      head &amp; neck cancer who are still active smokers ± alcohol misusers.The study will aim to
      compare the systematic implementation of an addiction treatment program initiated at
      hospital and integrated to the initial cancer treatment program (Arm A), versus the as-usual
      procedure, which consists in recommendations to follow an addiction treatment program (Arm
      B)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Study proposal at the first medical consultation for therapeutic management of a first
           upper aerodigestive tract cancer or lung cancer.

        -  Selection criteria validation

        -  Collection of an informed consent

        -  Randomization :

      Arm A: Experimental arm : Addiction consultation to the overall cancer treatment

      Arm B: standard of care

      The completion of questionnaires , the measurement of exhaled carbone monoxide rate using a
      CO tester for all patients, and the integrated addiction treatment among patients randomized
      in Arm A will not interfere with the medical treatment of cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the rates of tobacco abstinent patients at 12 months between arms A and B</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of alcohol and tobacco consumptions during the study</measure>
    <time_frame>initial diagnosis, after 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of tobacco abstinent patients at 12 months</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the rates of alcohol and tobacco abstinent patients at 12 months depending on whether or not they have received an addiction treatment</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time between inclusion date and the date of death (from any cause)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median progression-free time</measure>
    <time_frame>1 year</time_frame>
    <description>delay between inclusion date and progression date (clinical or radiological)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Arm A patients who attended the addiction treatment program after the first systematic consultation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Upper Aerodigestive Tract Neoplasms</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>integrated addiction treatment program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>integrated addiction treatment program</intervention_name>
    <description>At the inclusion, a 45 minutes interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I) , the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million (ppm) using the CO tester.
At 3, 6, and 12 months: a 20 minutes interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption.
The first addiction consultation will be carried out directly in the cancer treatment unit, and integrated to the overall cancer treatment program. This first addiction consultation will concern :
For patients with lung cancer: tobacco and addiction or harmful use of alcohol according to classical criteria
For patients with upper aerodigestive tract cancer: tobacco and any use of alcohol</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standard of care</intervention_name>
    <description>The following actions will be performed by a nurse or by the study coordinator on site who have been trained in tobaccology and addictology :
At the inclusion, a 45 minutes interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I) , the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million (ppm) using the CO tester.
At 3, 6, and 12 months: a 20 minutes interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a first upper aerodigestive tract cancer or a lung cancer

          -  Initial cancer treatment

          -  Aged ≥ 18 and ≤65 years

          -  Living within a radius of 20 km from the CHRU de Lille/Oscar Lambret Center

          -  Patient with tobacco addiction: regular smoker = at least 7 cigarettes /week or 1
             cigarette/day or short-term ex-smoker = regular smoker who has stopped smoking for
             less than 1 year from the inclusion date

          -  Performance status (ECOG/WHO) ≤ 2

          -  Registered with a social security system

          -  Informed and signed consent collected before initiation of any study procedures

        Exclusion Criteria:

          -  Previous lung cancer or upper aerodigestive tract cancer

          -  Previous other cancer &lt; 5 years, evoluting or treated at the inclusion (except
             uterine cervical carcinoma, basal cell or squamous cell skin carcinoma )

          -  Mesothelioma and esophageal cancer

          -  Occasional smoker (less than 7 cigarettes/week or less than 1 cigarette/day)

          -  Long-term ex-smokers who have stopped smoking for more than 1 year from the inclusion
             date

          -  Impossibility to comply with the study procedures due to geographic, social or mental
             reasons

          -  Patient under guardianship or tutorship

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne Vannimenus, MD</last_name>
    <role>Study Director</role>
    <affiliation>CHRU of Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corinne Vannimenus, MD</last_name>
    <phone>+ 33 3 20 44 66 55</phone>
    <email>corinne.vannimenus@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oscar Lambret Center</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gauthier Lefebvre, MD</last_name>
      <phone>+33 3 20 29 59 39</phone>
      <email>g-lefebvre@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Gauthier Lefebvre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU of Lille : Albert Calmette Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud Scherpereel, MD, PhD</last_name>
      <phone>+33 3 20 44 56 12</phone>
      <email>arnaud.scherpereel@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Arnaud Scherpereel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Corinne Vannimenus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU of Lille: Huriez Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Chevalier, MD</last_name>
      <phone>+33 3 20 44 66 86</phone>
      <email>dominique.chevalier@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique Chevalier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 17, 2015</lastchanged_date>
  <firstreceived_date>September 1, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alcohol and tobacco consumption</keyword>
  <keyword>addiction treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Behavior, Addictive</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
